Drug Trial Radar · NCT07332481
A Study of Enpatoran in Participants With Cutaneous Manifestations of Lupus With or Without Systemic Disease
Last checked: Nov 19, 2026Latest source record: Nov 4, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
202
Planned (sponsor's estimate)
Start
Mar 10, 2026
Primary completion
May 24, 2029
Study completion May 24, 2029
Sponsor
- Lead sponsor
- EMD Serono Research & Development Institute, Inc.Industry
- Sponsor type
- Industry
- Collaborators
- Merck KGaA, Darmstadt, Germany
- First posted
- Jan 12, 2026
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this global, multicenter, Phase 3 study is to evaluate the efficacy and safety of enpatoran over 24 weeks in participants with active cutaneous manifestations of lupus erythematosus with or without systemic disease. Study details include: Study Duration: Up to 35 weeks. Treatment Duration: 24 weeks. Visit Frequency: every 4 weeks, with the exception of the Week 2 televisit. Study Intervention Name: Enpatoran, Placebo. Intervention Form: Film-coated tablet.
Conditions
- Systemic Lupus Erythematosus (SLE)
- Cutaneous Lupus Erythematosus (CLE)
Interventions
EnpatoranDrug
Participants will receive a dose of Enpatoran orally twice daily from Day 1 to Day 168.
PlaceboDrug
Participants will receive a single oral dose of a placebo matching Enpatoran tablet twice daily from Day 1 to Day 168.
Standard of care (SoC)Drug
Participants will receive Investigator-recommended SoC.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants With Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) 70 Response, Defined as >= 70 Percent (%) Decrease in CLASI-A Score From BaselineTime frame: At Week 24
Locations
74 sites in 20 countries. Site status is shown where the registry gives one.
Dermatology Research Associates - 300204025
Los Angeles, California · Recruiting
Cohen Medical Centers
Thousand Oaks, California · Recruiting
GNP Research at Mark Jaffe, MD
Cooper City, Florida · Recruiting
Advance Medical Research Center
Miami, Florida · Recruiting
Diverse Clinical Research LLC
Miami, Florida · Recruiting
D&H National Research Centers, Inc.
Tamarac, Florida · Recruiting
Clinical Research of West Florida, Inc.
Tampa, Florida · Recruiting
Emory University School of Medicine
Atlanta, Georgia · Recruiting
Revival Research Institute, LLC
Troy, Michigan · Recruiting
Allen Arthritis
Allen, Texas · Recruiting
Arthritis and Rheumatology Research Institute PLLC
Allen, Texas · Recruiting
Arthritis Care of Texas
Corpus Christi, Texas · Recruiting
John Hunter Hospital - PARENT
New Lambton Heights, New South Wales, Australia · Recruiting
Rheumatology Research Unit Sunshine Coast
Maroochydore, Queensland, Australia · Recruiting
The Alfred Hospital - PARENT
Melbourne, Victoria, Australia · Recruiting
UZ Leuven - Internal Medicine
Leuven, Belgium · Recruiting
HUWC - UFC - Hospital Universitário Walter Cantídio - Universidade Federal do Ceará
Fortaleza, Ceará, Brazil · Recruiting
Clínica SER da Bahia
Salvador, Estado de Bahia, Brazil · Recruiting
IPC MT Instituto de Pesquisas Clinicas do Mato Grosso
Cuiabá, Mato Grosso, Brazil · Recruiting
Freire Pesquisa Clinica
Belo Horizonte, Minas Gerais, Brazil · Recruiting
Hospital de Câncer de Barretos - Fundação Pio XII - Hospital de Amor de Barretos
Barretos, São Paulo, Brazil · Recruiting
DCC V Plovdiv Sv. Archbishop Luka EOOD
Plovdiv, Bulgaria · Recruiting
Ambulatory for Specialized Medical Help - skin and venereal diseases
Sofia, Bulgaria · Recruiting
Guangdong Provincial People's Hospital
Guangzhou, Guangdong, China · Recruiting
Ganzhou People's Hospital - 300165192
Ganzhou, Jiangxi, China · Recruiting
Hopital Tenon - service dermatologie et centre d'allergie
Paris, France · Recruiting
CHU Saint Etienne - Hôpital Nord - service de medecine interne
Saint-Étienne-de-Montluc, Pays de la Loire Region, France · Recruiting
Charité - Campus Charité Mitte - Klinik fuer Dermatol., Venerol., Allergologie
Berlin, Germany · Recruiting
Universitaetsklinikum Carl Gustav Carus TU Dresden
Dresden, Germany · Recruiting
Elbekliniken Buxtehude GmbH - Dermatologie
Buxtehude, Lower Saxony, Germany · Recruiting
Chaim Sheba Medical Center - pt
Ramat Gan, Israel · Recruiting
Università Campus Bio-Medico di Roma - UOC Reumatologia
Roma, Italy · Recruiting
Azienda USL Toscana Centro - Ospedale Piero Palagi
Florence, Firenze, Italy · Recruiting
JCHO Chukyo Hospital - Dept of Dermatology
Nagoya, Aichi-ken, Japan · Recruiting
NHO Chibahigashi National Hospital - Dept of Allergy/Rheumatology
Chiba, Chiba, Japan · Recruiting
Hospital of the University of Occupational and Environmental Health - Dept of Dermatology
Kitakyushu-shi, Fukuoka, Japan · Recruiting
Fukushima Medical University Hospital - Dept of Rheumatology/Immunology
Fukushima, Fukushima, Japan · Recruiting
NHO Asahikawa Medical Center - Dept of Gastroenterology
Asahikawa-shi, Hokkaido, Japan · Recruiting
Sapporo City General Hospital - Dept of Rheumatology/Immunology
Sapporo, Hokkaido, Japan · Recruiting
Kobe University Hospital - Dept of Immunology/Rheumatology
Kobe, Hyōgo, Japan · Recruiting
Showing 40 of 74 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.